Eli Lilly and Co

NYSE:LLYUnited States

Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.

Contact Information

Headquarters

Lilly Corporate Ctr Drop Code 1094, Lilly Corporate CtrINDIANAPOLIS, IN, United States 46285-0001

Phone

317-276-2000

Fax

317-276-3492

Executives

Chairman of the Board, President, Chief Executive Officer

David Ricks

Interim Chief Financial Officer

Gordon Brooks

Executive Vice President, Chief Information and Digital Officer

Diogo Rau

Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology

Daniel Skovronsky

Executive Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer

Alonzo Weems